Low P2/MS value is an independent risk factor for early recurrence of hepatocellular carcinoma after radiofrequency ablation therapy.
The influence of liver fibrosis on the recurrence of hepatocellular carcinoma after ablation therapy has not been fully elucidated. We previously reported that P2/MS [(platelet count [10(9)/L])2/(monocyte fraction[%] x segmented neutrophil fraction[%])] is an effective and noninvasive marker reflecting the degree of hepatic fibrosis. We aimed to evaluate the relationship between P2/MS value and hepatocellular carcinoma recurrence after radiofrequency ablation therapy in this study. Chronic hepatitis B patients who underwent RFA for hypervascular single hepatocellular carcinoma at Seoul National University Hospital between 2004 and 2007 were prospectively included. We identified the predictors of recurrence using Cox-regression model. Fifty one patients were included. Median follow-up duration was 14.2 months. Twenty patients experienced tumor recurrence. Multivariable analyses showed that low P2/MS level [HR, 0.97 (95% CI, 0.95-0.99); p = 0.008] and alpha-fetoprotein level >100 ng/mL [HR, 8.65 (95% CI, 2.37-31.67); p = 0.001] were independent risk factors for tumor recurrence. Patients with P2/MS < 45.0 showed 3.68-fold (p = 0.048) increase in the risk of recurrence compared to those with P2/MS > or =45.0. However, tumor size, HBeAg and HBV DNA level failed to significantly affect the time-to-recurrence. Our study suggests that low P2/MS value, which indicates high grade of hepatic fibrosis, is an independent risk factor for HBV-related hepatocellular carcinoma recurrence after radiofrequency ablation.